FDA's 2026 warning letters to telehealth companies: what was cited
On 3 March 2026 the FDA announced warning letters to 30 telehealth companies for false or misleading claims about compounded GLP-1 products on their websites, and on 16 June 2026 it issued 25 more. The two violations FDA named were claims implying sameness with FDA-approved products and advertising drug products branded with the telehealth firm's own name without qualification. FDA also published a page on what to know when promoting compounded drugs.
What happened
FDA's March announcement described the letters as the second enforcement action against telehealth firms under a direct-to-consumer advertising initiative launched in September 2025, under which the agency said it had sent thousands of letters to pharmaceutical and telehealth companies in six months. The letters allege misbranding under the Federal Food, Drug, and Cosmetic Act. FDA Commissioner Marty Makary said compounded drugs serve legitimate purposes but should not be used to circumvent the approval process. The June letters, reported by law firms and trade press, cited compounded semaglutide, tirzepatide and in one case liraglutide.
Confirmed versus interpretation
Confirmed (primary source): the dates, the counts, the two named violation types, the existence of the compounded-drug promotion guidance page. Our interpretation: the letters are about website copy at page level. Titles, product names, comparison tables, FAQs and advertorials are all promotional material in FDA's reading.
Search and content implications
- Comparison pages have to describe and cite, not equate. "Same as", "identical to", "generic [brand]" are red on a compounded-product page.
- Company-branded product names need a qualification saying who compounds the product.
- Any implied approval language ("FDA-approved", "FDA-registered facility" used to imply product approval) is red unless it is a disclosure that the product is not approved.
- Removing or rewriting cited pages costs rankings; planning the rewrite with the search map in hand costs less than a takedown.
Escalation
Whether a given page, claim or product name creates exposure is a question for your counsel. This brief records what FDA said publicly and how we write because of it.
Sources
- FDA press announcement: FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s (2026-03-03) — https://www.fda.gov/news-events/press-announcements/fda-warns-30-telehealth-companies-against-illegal-marketing-compounded-glp-1-s
- FDA: What to know when promoting compounded drugs — https://www.fda.gov/drugs/human-drug-compounding/what-know-when-promoting-compounded-drugs
- FDA warning letter to MEDVi, LLC (2026-02-20) — https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/medvi-llc-dba-medvi-721455-02202026
- National Law Review: FDA's focus returns to compounding and telehealth (June 2026 letters) — https://natlawreview.com/article/fdas-focus-returns-compounding-and-telehealth-another-wave-warning-letters
GLP-1SEO provides search-marketing services and publishes search-marketing analysis. We are not physicians, pharmacists, lawyers or regulatory consultants, and nothing on this site is medical, legal or regulatory advice, or advice to patients. Clients remain responsible for obtaining qualified advice about their products, claims, jurisdictions and operations.